Using nanoparticle vaccines to treat brain tumors
Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas
This study is exploring a new way to help people with gliomas, a type of brain tumor, by using special vaccines made from tiny particles that can reach the brain and boost the immune system to fight the tumor better, especially for those who haven't had success with regular treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11030736 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating gliomas, a type of brain tumor, by using RNA-nanoparticle vaccines that can cross the blood-brain barrier. The study aims to activate the immune system's response against tumors by delivering tumor-specific mRNA in a way that enhances both innate and adaptive immunity. By utilizing a multi-lamellar nano-lipid formulation, the researchers hope to improve the effectiveness of immunotherapy in patients with gliomas, particularly those who have not responded to traditional treatments. The research includes testing in animal models to ensure safety and efficacy before potential human application.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with gliomas who have not responded to existing therapies or are seeking new treatment options.
Not a fit: Patients with gliomas who are in advanced stages of the disease with no viable treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients with gliomas, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promising results with similar nanoparticle approaches in animal models, indicating potential for success in human applications.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Sayour, Elias — University of Florida
- Study coordinator: Sayour, Elias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.